Inclusive practices for safe and equitable donor assessment

W Warren Fingrut (1MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, United States) E Eefke van Eerden (4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands) T Terrie Foster (5Canadian Blood Services, Ottawa, Canada) C Caitlin Sarubbi (6Montefiore Medical Center/Albert Einstein College of Medicine, Department of Medicine, Bronx, United States) F Felipe Acuña (4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands) I Isabel Auer (4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands) M Meghann Cody (4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands) G Grzegorz Hensler (4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands) C Charlotte Ingram (4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands) C Charles Loh (11Bone Marrow Donor Programme, Singapore, Singapore) D Danielli Oliveira (4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands) J Jonas Rieping (4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands) H Hung Yang (4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands) J Jane Ward T Thilo Mengling (4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands) J Jason Oakes (4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands) C Chloe Anthias (1Royal Marsden Hospital, London, United Kingdom)

Abstract

Abstract Background: Guidance is needed to optimize the recruitment, verification typing (VT) and workup of donors from vulnerable populations and to overcome structural barriers to donation. Purpose: In 2022, the World Marrow Donor Association (WMDA) Donor Medical Suitability Committee set out to advance health equity in donor suitability guidance (published to https://share.wmda.info/display/LP/Donor+Suitability+Pages+index ). Our goals were to harmonize global practices for donor assessments, and concurrently advance health equity and donation safety for patients and donors. Expanding on this work, here, we report the development of recommendations on inclusive practices for safe and equitable donor assessments. Methods: A project group was assembled including representation from donor registries worldwide, specialists in stem cell transplantation, donor care and follow-up, and cellular therapy, and healthcare providers with lived experience with and/or expertise caring for vulnerable populations, across the intersectionality of race, ethnicity, sex, gender identity, sexual orientation, socioeconomic status, and disability. The group met regularly to develop consensus recommendations, as well as tools to guide implementation. Guidance developed focused on potential unrelated peripheral blood stem cell, bone marrow, and maternal cord blood donors, with most recommendations also being applicable to related allograft, autologous stem cell, and cell therapy product donors. Results: We developed a series of recommendations for inclusive practices for safe and equitable assessment of donors from vulnerable populations. Recommendations emphasized that health equity should be prioritized alongside donation safety, and provided guidance on donor/ transplant center communication with donors, donor health history questionnaire design, deferral criteria at registration, VT, or workup, reporting requirements for donor centers to transplant centers and to recipients (balancing clinical decision making/patient safety with donor privacy/confidentiality), and equity in laboratory testing and evaluation. Specific recommendations focused on donors who are racialized, transgender or non-binary, facing social (e.g. language), cultural, or financial barriers, living with disabilities or mental health challenges, or those who are living with HIV, taking HIV pre- or post-exposure prophylaxis, or have a history of high-risk sexual behavior, non-prescription injection drug use, incarceration, or sex work. Tools developed to guide implementation included inclusive donor screening questionnaires, scripts, workflows, and training to guide collection, reporting, and use of sensitive donor data, and algorithms to guide clinical decision making for vulnerable populations. Conclusions: These guidelines and tools will support stakeholders across transplantation and cellular therapy, including donor and transplant centers and all medical teams involved in donor assessments, to advocate for donation policies and practices which uplift, include, support, and empower donors from marginalized groups. Implementing these recommendations will help dismantle structural barriers to donation, improve donor well-being and enhance donation experience, and advance a more inclusive healthcare system for donors from vulnerable populations.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 2648-2648
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (17)

W

Warren Fingrut

1MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, United States

E

Eefke van Eerden

4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands

T

Terrie Foster

5Canadian Blood Services, Ottawa, Canada

C

Caitlin Sarubbi

6Montefiore Medical Center/Albert Einstein College of Medicine, Department of Medicine, Bronx, United States

F

Felipe Acuña

4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands

I

Isabel Auer

4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands

M

Meghann Cody

4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands

G

Grzegorz Hensler

4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands

C

Charlotte Ingram

4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands

C

Charles Loh

11Bone Marrow Donor Programme, Singapore, Singapore

D

Danielli Oliveira

4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands

J

Jonas Rieping

4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands

H

Hung Yang

4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands

J

Jane Ward

T

Thilo Mengling

4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands

J

Jason Oakes

4Donor Medical Suitability Committee, World Marrow Donor Association, Leiden, Netherlands

C

Chloe Anthias

1Royal Marsden Hospital, London, United Kingdom